• Home
  • Leadership
    • Management Team
    • Advisors
    • Scientific Advisory Board
    • Board of Directors
  • Therapeutic Programs
  • Media
  • Contact
UNC-Chapel Hill gene therapy spinout raises $1.4 million

UNC-Chapel Hill gene therapy spinout raises $1.4 million

by Damon Race | Sep 12, 2022 | In the News

By Zac Ezzone  –  Staff writer, Triangle Business Journal Sep 1, 2022 A UNC-Chapel Hill spinout developing gene therapies focused on rare blood diseases and disorders has raised $1.4 million to support its efforts. The company, GeneVentiv Therapeutics, raised the...
GeneVentiv Receives Orphan Drug Designation (ODD) for GENV-HEM for the treatment of Hemophilia A or B with or without inhibitors

GeneVentiv Receives Orphan Drug Designation (ODD) for GENV-HEM for the treatment of Hemophilia A or B with or without inhibitors

by Damon Race | Nov 2, 2021 | Press

Preclinical data provide quantitative evidence of GENV-HEM’s ability to achieve phenotypic correction in animal models of hemophilia, independent of the presence of any clotting factor inhibitors. Estimated 95,000 patients in the U.S. and Europe represent...
100+ companies will participate in CED’s Venture Connect – here’s who made the cut

100+ companies will participate in CED’s Venture Connect – here’s who made the cut

by Damon Race | Feb 5, 2021 | In the News

by WRAL TechWire — January 29, 2021 RESEARCH TRIANGLE PARK – More than 100 startups and emerging entrepreneurial companies will participate in the Venture Connect 2021 summit, the Council for Entrepreneurial Development announced today. The event is set for March...
Next Entries »

Recent Posts

  • Gene therapy developed at Duke to be commercialized by a local biotechnology company
  • GeneVentiv Announces Global Licensing Agreement for Universal Gene Editing Therapy for Infantile Onset and Late Onset Pompe Disease
  • GeneVentiv Welcomes New Scientific Advisory Board Member, Sylvia Fong
  • GeneVentiv Therapeutics Awarded $2.5 Million SBIR Grant to Advance Gene Therapy for All Hemophilias, with or without Inhibitors
  • New partners to develop universal gene therapy for hemophilia

Recent Comments

    Archives

    • April 2025
    • July 2024
    • April 2024
    • March 2024
    • January 2024
    • November 2023
    • October 2023
    • September 2023
    • August 2023
    • May 2023
    • April 2023
    • February 2023
    • January 2023
    • September 2022
    • June 2022
    • March 2022
    • February 2022
    • November 2021
    • March 2021
    • February 2021
    • January 2021
    • November 2020
    • October 2020

    Categories

    • In the News
    • Press

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Contact Us

    • Please prove you are human by selecting the Plane.
    • This field is for validation purposes and should be left unchanged.
    • Follow
    Copyright © 2025 GeneVentiv Therapeutics. All rights reserved.
    • Follow